Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells 1,000 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $69.74, for a total value of $69,740.00. Following the sale, the insider owned 37,793 shares in the company, valued at $2,635,683.82. The trade was a 2.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Friday, January 2nd, Rahul Khara sold 6,500 shares of Disc Medicine stock. The stock was sold at an average price of $78.69, for a total value of $511,485.00.

Disc Medicine Stock Up 1.2%

IRON stock traded up $0.89 during trading on Wednesday, reaching $74.89. 440,486 shares of the company’s stock were exchanged, compared to its average volume of 421,813. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $85.06 and its 200-day moving average price is $72.95. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, sell-side analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th. Wedbush reaffirmed an “outperform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Stifel Nicolaus began coverage on Disc Medicine in a report on Monday, November 3rd. They set a “buy” rating and a $125.00 price target on the stock. Wells Fargo & Company increased their price target on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Cantor Fitzgerald lifted their price objective on Disc Medicine from $132.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, October 17th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.45.

Hedge Funds Weigh In On Disc Medicine

Institutional investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP raised its holdings in shares of Disc Medicine by 257.1% in the third quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock valued at $33,040,000 after buying an additional 360,000 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Disc Medicine by 3,329.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after acquiring an additional 347,403 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Disc Medicine in the third quarter worth about $22,342,000. First Light Asset Management LLC bought a new position in shares of Disc Medicine in the third quarter worth about $15,277,000. Finally, Sio Capital Management LLC grew its stake in shares of Disc Medicine by 287.4% during the second quarter. Sio Capital Management LLC now owns 284,787 shares of the company’s stock valued at $15,082,000 after purchasing an additional 211,276 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.